This site contains promotional information intended only for healthcare professionals resident in Great Britain 
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

For Inflectra® (infliximab) Prescribing Information for Great Britain click here.
Adverse event reporting information can be found at the bottom of the page.

Safety profile and efficacy Contraindications

Ulcerative Colitis safety guidance

In Adults

Inflectra is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.1 

In Paediatrics

Inflectra is indicated for treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.1

Post-marketing safety

Post-marketing data of 4,393 patients has illustrated that the safety profile appears consistent with clinical studies for CT-P13 and reference infliximab, supporting the favourable risk/benefit balance for CT-P13 treatment.2

​​​​​​​Please see the link for Inflectra® (infliximab) Prescribing Information at the top of the page, and refer to Section 4.8 for a summary of the safety profile.

Explore more

Evidence – inflammatory bowel disease

Learn about the clinical evidence supporting the use of Inflectra inpatients with ulcerative colitis and crohn’s disease

Learn more

Ulcerative colitis dosing

Learn about the dosing and administration of Inflectra in patients with Ulcerative colitis

Find out more
References
  1. Inflectra Summary of Product Characteristics.
  2. Lee SJ, et al. BioDrugs 2020 :doi : 10.1007/s40259-020-00421-2.
PP-IFA-GBR-0509. September 2021

Quick Links

Read about the safety profile and contraindications with Inflectra in patients with rheumatoid arthritis. 

Find out more

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?